NCT00121849View on ClinicalTrials.gov

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

February 28, 2006

Conditions
Cutaneous Leishmaniasis
Interventions
BIOLOGICAL

Leish-111f + MPL-SE vaccine

Trial Locations (1)

Unknown

Programa de Estudio y Control de Enfermedades Tropicales (PECET), Medellín

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Access to Advanced Health Institute (AAHI)

OTHER

NCT00121849 - Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite | Biotech Hunter | Biotech Hunter